Drug Trial Radar · NCT04474314
A Study of IMR-687 in Subjects With Sickle Cell Disease
Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
115
Actual
Start
Aug 13, 2020
Primary completion
Mar 2, 2022
Study completion May 4, 2022
Sponsor
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Imara, Inc.
- First posted
- Jul 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study to Evaluate the Safety and Efficacy of IMR-687 in Subjects with Sickle Cell Disease
Conditions
- Sickle Cell Disease
Interventions
IMR-687Drug
Oral administration of once daily IMR-687
PlaceboDrug
Oral administration of once daily Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effect on the Incidence of Vaso-occlusive Crises (VOCs)Time frame: Baseline to Week 52
- Proportion of Patients With Adverse Events and Serious Adverse EventsTime frame: Baseline to Week 56
Locations
49 sites in 13 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham School of Medicine - 1917 Clinic
Birmingham, Alabama
Arkansas Primary Care Clinic
Little Rock, Arkansas
University of California San Diego Moores Cancer Center
La Jolla, California
Center For Inherited Blood Disorders
Santa Ana, California
The Oncology Institute Long Beach
Whittier, California
University of Connecticut Health Main Building
Farmington, Connecticut
Children's Healthcare of Atlanta
Atlanta, Georgia
The University of Illinois at Chicago College of Medicine
Chicago, Illinois
Johns Hopkins Hospital
Baltimore, Maryland
Children's Hospital of Michigan
Detroit, Michigan
Newark Beth Israel Medical Center
Newark, New Jersey
Weill Cornell Medicine - Center for Blood Disorders
New York, New York
Baylor Scott & White Medical Center-Temple
Temple, Texas
Virginia Commonwealth University Health - Ambulatory Care Center
Richmond, Virginia
Korle Bu Teaching Hospital
Accra, Ghana
Kintampo Health Research Centre
Kintampo, Ghana
University General Hospital of Patras
Pátrai, Greece
Ippokrateio General Hospital of Thessaloniki
Thessaloniki, Greece
Laiko General Hospital of Athens
Athens, Attica, Greece
Ente Ospedaliero Ospedali Galliera
Genoa, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
Palermo, Italy
Azienda Ospedaliero - Universitaria San Luigi Gonzaga
Turin, Orbassano, Italy
Fondazione Policlinico Universitario Agostino Gemelli
Roma, Rome, Italy
Gertrude's Children's Hospital
Nairobi, Kenya
The Centre for Respiratory Diseases Research - Kenya Medical Research Institute
Nairobi, Kenya
Kenya Medical Research Institute - Kisumu
Kisumu, Nyanza, Kenya
American University of Beirut Medical Center
Beirut, Lebanon
Chronic Care Center
Hazmiyeh, Lebanon
Hopital Nini
Tripoli, North Governorate, Lebanon
Hôpital d'Enfants Rabat
Rabat, Morocco
Hagaziekenhuis Van Den Haag - Leyweg
The Hague, South Holland, Netherlands
Sultan Qaboos University Hospital
Muscat, Oman
Centre National De Transfusion Sanguine - Du Senegal
Dakar, Senegal
Hedi Chaker Hospital
Sfax, Tunisia
Centre Hôpital Universitaire Farhat Hached
Sousse, Tunisia
Centre National de Greffe de la Moelle Osseuse
Tunis, Tunisia
Hospital Aziza Othmana
Tunis, Tunisia
Jinja Regional Referral Hospital
Jinja, Uganda
Uganda Cancer Institute
Kampala, Uganda
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.